PubMed Health⌕ Search

Biomedical subjects

A R Lorimer

Publications and source records attributed to A R Lorimer.

At least 127 records · Page 7Linked to original sources
PubMed1969

Blood pressure in a Scottish island community.

A survey of mean blood pressure levels in age-and-sex-matched samples of the population of the island of Tiree appears to support the local belief that blood pressure is higher on the island than on the mainland. This conclusion may be related to the observation of a greater mean width of the heart, measured radiologically, in the island population compared with the mainland population. The greater mean body weight observed in the island compared with the mainland may be a factor. Blood pressure in men between the ages of 40 and 59 years is higher in Tiree than in selected samples in England and America.

Adolescent↗
PubMedDate not supplied

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.

This study examines the kinetic basis for the increment in plasma low density lipoprotein (LDL) levels that accompanies the fenofibrate treatment of severely hypertriglyceridemic (HTG) patients. Seven HTG men with a mean plasma triglyceride level of 1470 mg/dl were treated for 6 weeks. During treatment, their plasma triglyceride level fell by 77% and their cholesterol level by 41%. The fall in very low density lipoprotein (VLDL) cholesterol level was reciprocated by increments in the cholesterol level in both LDL and high density lipoproteins (HDL); the rise in HDL was confined to HDL3. LDL catabolism was examined before and during therapy using native and chemically modified tracers in an attempt to distinguish receptor-mediated from non-receptor-mediated clearance. In their basal state, the hypertriglyceridemic subjects overcatabolized both the native and the modified lipoprotein, implying that the non-receptor pathways were hyperactive. The mean fractional clearance rate of LDL via the receptor pathway was not significantly different from normal. Fenofibrate therapy corrected the patients' hypercatabolism, reducing the receptor-independent fractional clearance of apo LDL by 50% (from 0.48 to 0.24 pools/day; p less than 0.05). The mean fractional catabolic activity of the receptor route did not change, but when the increment in the plasma apo LDL concentration was taken into account, it was clear that the drug treatment was associated with an increase in the net amount cleared by the receptor pathway and with a reduction of lipoprotein uptake into receptor-independent routes.

Adult↗